Literature DB >> 6744320

Lymphoid cell subpopulations infiltrating into autologous rat tumors undergoing rejection.

Y Ishii, A Matsuura, T Takami, T Uede, Y Ibayashi, T Uede, M Imamura, K Kikuchi, Y Kikuchi.   

Abstract

Lymphoid cell subpopulations infiltrating into autografts of methylcholanthrene-induced sarcomas in rats immunized with autologous tumor cells were identified in terms of immunohistochemical and cytofluorographic techniques using various monoclonal antibodies raised against different classes of rat lymphohemopoietic cells. These antibodies included in this study directed to rat T-cell antigens corresponding to mouse Lyt-1 (RLyt-1) and Lyt-2,3 antigens (RLyt-2) and to W3/25 antigen expressed on a particular subset of rat T-cells with helper function, as well as to rat granulocyte-macrophage-specific antigen (RGM-1). Histological studies demonstrated that the autografts of highly antigenic tumors introduced to the primary hosts were completely rejected following massive immigration of lymphoid cells into the tumor sites, which was not observed in progressively growing, minimally antigenic tumors. These lymphoid cells found within regressing highly antigenic tumor autografts were identified mostly to be T-cells bearing RLyt-1 (approximately 70%), and more than two-thirds of these T-cells expressed RLyt-2 antigen. In contrast to T-cells, macrophages and B-cells, each of which could be recognized by the presence of either RGM-1 antigen or immunoglobulin on their cell surfaces, appeared to have a minimal role in the rejection of autochthonous tumors, as reflected by their less frequent appearance within the tumor tissues during the rejection process.

Entities:  

Mesh:

Year:  1984        PMID: 6744320

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens.

Authors:  S Sano; Y Izumi; S Sugihara; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  In vitro analysis of cancer prevention by a mycobacterial antigen complex and of cancer-promoted inhibition of immune reactions.

Authors:  H Maes; C Cocito
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Macrophages and T lymphocytes infiltrating the rat mammary carcinoma HH9-cl 14 in progressive and regressive tumor growth. An immunohistological study.

Authors:  E Vollmer; F Shimamoto; V Krieg; E Grundmann
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  Principal lymphocyte subpopulation in local host response to human oesophageal cancer.

Authors:  H Tahara; H Siozaki; K Kobayashi; H Yano; S Tamura; M Miyata; K Wakasa; M Sakurai; T Mori
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

5.  Different distributions of T cell subsets between perivascular and interstitial peritubular areas during rejection of rat renal allografts: a quantitative and ultrastructural study using monoclonal antibodies.

Authors:  H Ishikura; A Matsuura; Y Ishii; T Natori; K Kikuchi; M Aizawa
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

6.  Two distinct mechanisms involved in the infiltration of lymphocytes into tumors.

Authors:  N Shijubo; T Uede; T Takami; Y Torimoto; D Lupin; S Min; K Kikuchi
Journal:  Jpn J Cancer Res       Date:  1988-10

7.  Immunotherapy of solid tumor by intratumoral infusion of lymphokine-activated killer cells.

Authors:  T Yamaki; Y Ibayashi; T Nakamura; N Shijubo; M Daibo; T Kawahara; K Hashi
Journal:  Jpn J Cancer Res       Date:  1988-08

8.  Functional analysis of mononuclear cells infiltrating into tumors: establishment of T cell hybridomas exhibiting distinct interacting abilities with endothelial cells and extracellular matrix components.

Authors:  E Uno; K Kikuchi; I Saiki; T Uede
Journal:  Jpn J Cancer Res       Date:  1993-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.